Longeveron Receives FDA Fast Track Designation For Lomecel-B For Mild Alzheimer's Disease; Second Designation Following RMAT Designation On July 9, 2024
Longeveron Receives FDA Fast Track Designation For Lomecel-B For Mild Alzheimer's Disease; Second Designation Following RMAT Designation On July 9, 2024
Longeveron因Lomecel-b治疗轻度阿尔茨海默病获得FDA快速通道认定，2024年7月9日获得RMAt认定后的第二个认定
Phase 2a Data To Be Presented At Alzheimer's Association International Conference; Lomecel-B Is An Allogeneic Investigational Cellular Therapy Also Evaluated For Aging-Related Frailty And Hypoplastic Left Heart Syndrome
第二阶段数据将在阿尔茨海默协会国际会议上公布; Lomecel-b是一种异基因的实验性细胞治疗，也被用于评估与衰弱和低发育性左心综合征有关的衰老相关问题。
资讯热榜
更新时间